Baseline-Status und Dosis auf den Bulbus penis als Prädiktoren für Impotenz ein Jahr nach Radiotherapie bei Prostatakrebs

Translated title of the contribution: Baseline status and dose to the penile bulb predict impotence 1 year after radiotherapy for prostate cancer

Cesare Cozzarini, Tiziana Rancati, Fabio Badenchini, Federica Palorini, Barbara Avuzzi, Claudio Degli Esposti, Giuseppe Girelli, Ilaria Improta, Vittorio Vavassori, Riccardo Valdagni, Claudio Fiorino

Research output: Contribution to journalArticle

Abstract

Aim: To assess the predictors of the onset of impotence 1 year after radiotherapy for prostate cancer. Patients and methods: In a multi-centric prospective study, the International Index of Erectile Function (IIEF) questionnaire-based potency of 91 hormone-naïve and potent patients (IIEF1-5 > 11 before radiotherapy) was assessed. At the time of this analysis, information on potency 1 year after treatment was available for 62 of 91 patients (42 treated with hypofractionation: 2.35–2.65 Gy/fr, 70–74.2 Gy; 20 with conventional fractionation: 74–78 Gy). Prospectively collected individual information and Dmax/Dmeanto the penile bulb were available; the corresponding 2 Gy-equivalent values (EQD2_max/EQD2_mean) were also considered. Predictors of 1‑year impotency were assessed through uni- and multi-variable backward logistic regression: The best cut-off values discriminating between potent and impotent patients were assessed by ROC analyses. The discriminative power of the models and goodness-of-fit were measured by AUC analysis and the Hosmer–Lemeshow (H&L) test. Results: At 1‑year follow-up, 26 of 62 patients (42 %) became impotent. The only predictive variables were baseline IIEF1-5 values (best cut-off baseline IIEF1-5 ≥ 19), Dmax≥ 68.5 Gy and EQD2_max≥ 74.2 Gy. The risk of 1‑year impotence may be predicted by a two-variable model including baseline IIEF1-5 (OR: 0.80, p = 0.003) and EQD2_max≥ 74.2 Gy (OR: 4.1, p = 0.022). The AUC of the model was 0.77 (95% CI: 0.64–0.87, p = 0.0007, H&L: p = 0.62). The 1‑year risk of impotency after high-dose radiotherapy in potent men depends on the EQD2_maxto the penile bulb and on baseline IIEF1-5 values. Conclusion: A significant reduction in the risk may be expected mainly when sparing the bulb in patients with no/mild baseline impotency (IIEF1-5 > 17).

Original languageGerman
Pages (from-to)297-304
Number of pages8
JournalStrahlentherapie und Onkologie
Volume192
Issue number5
DOIs
Publication statusPublished - May 1 2016

Fingerprint

Erectile Dysfunction
Prostatic Neoplasms
Radiotherapy
Area Under Curve
Risk Reduction Behavior
ROC Curve
Logistic Models
Hormones
Prospective Studies
Therapeutics

Keywords

  • Dose-response
  • Erectile dysfunction
  • Predictive models
  • Prostate cancer
  • Radiotherapy

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Oncology

Cite this

Baseline-Status und Dosis auf den Bulbus penis als Prädiktoren für Impotenz ein Jahr nach Radiotherapie bei Prostatakrebs. / Cozzarini, Cesare; Rancati, Tiziana; Badenchini, Fabio; Palorini, Federica; Avuzzi, Barbara; Degli Esposti, Claudio; Girelli, Giuseppe; Improta, Ilaria; Vavassori, Vittorio; Valdagni, Riccardo; Fiorino, Claudio.

In: Strahlentherapie und Onkologie, Vol. 192, No. 5, 01.05.2016, p. 297-304.

Research output: Contribution to journalArticle

Cozzarini, Cesare ; Rancati, Tiziana ; Badenchini, Fabio ; Palorini, Federica ; Avuzzi, Barbara ; Degli Esposti, Claudio ; Girelli, Giuseppe ; Improta, Ilaria ; Vavassori, Vittorio ; Valdagni, Riccardo ; Fiorino, Claudio. / Baseline-Status und Dosis auf den Bulbus penis als Prädiktoren für Impotenz ein Jahr nach Radiotherapie bei Prostatakrebs. In: Strahlentherapie und Onkologie. 2016 ; Vol. 192, No. 5. pp. 297-304.
@article{862d3e0f8c2f44948db0a73f7e510092,
title = "Baseline-Status und Dosis auf den Bulbus penis als Pr{\"a}diktoren f{\"u}r Impotenz ein Jahr nach Radiotherapie bei Prostatakrebs",
abstract = "Aim: To assess the predictors of the onset of impotence 1 year after radiotherapy for prostate cancer. Patients and methods: In a multi-centric prospective study, the International Index of Erectile Function (IIEF) questionnaire-based potency of 91 hormone-na{\"i}ve and potent patients (IIEF1-5 > 11 before radiotherapy) was assessed. At the time of this analysis, information on potency 1 year after treatment was available for 62 of 91 patients (42 treated with hypofractionation: 2.35–2.65 Gy/fr, 70–74.2 Gy; 20 with conventional fractionation: 74–78 Gy). Prospectively collected individual information and Dmax/Dmeanto the penile bulb were available; the corresponding 2 Gy-equivalent values (EQD2_max/EQD2_mean) were also considered. Predictors of 1‑year impotency were assessed through uni- and multi-variable backward logistic regression: The best cut-off values discriminating between potent and impotent patients were assessed by ROC analyses. The discriminative power of the models and goodness-of-fit were measured by AUC analysis and the Hosmer–Lemeshow (H&L) test. Results: At 1‑year follow-up, 26 of 62 patients (42 {\%}) became impotent. The only predictive variables were baseline IIEF1-5 values (best cut-off baseline IIEF1-5 ≥ 19), Dmax≥ 68.5 Gy and EQD2_max≥ 74.2 Gy. The risk of 1‑year impotence may be predicted by a two-variable model including baseline IIEF1-5 (OR: 0.80, p = 0.003) and EQD2_max≥ 74.2 Gy (OR: 4.1, p = 0.022). The AUC of the model was 0.77 (95{\%} CI: 0.64–0.87, p = 0.0007, H&L: p = 0.62). The 1‑year risk of impotency after high-dose radiotherapy in potent men depends on the EQD2_maxto the penile bulb and on baseline IIEF1-5 values. Conclusion: A significant reduction in the risk may be expected mainly when sparing the bulb in patients with no/mild baseline impotency (IIEF1-5 > 17).",
keywords = "Dose-response, Erectile dysfunction, Predictive models, Prostate cancer, Radiotherapy",
author = "Cesare Cozzarini and Tiziana Rancati and Fabio Badenchini and Federica Palorini and Barbara Avuzzi and {Degli Esposti}, Claudio and Giuseppe Girelli and Ilaria Improta and Vittorio Vavassori and Riccardo Valdagni and Claudio Fiorino",
year = "2016",
month = "5",
day = "1",
doi = "10.1007/s00066-016-0964-1",
language = "Tedesco",
volume = "192",
pages = "297--304",
journal = "Strahlentherapie und Onkologie",
issn = "0179-7158",
publisher = "Urban und Vogel",
number = "5",

}

TY - JOUR

T1 - Baseline-Status und Dosis auf den Bulbus penis als Prädiktoren für Impotenz ein Jahr nach Radiotherapie bei Prostatakrebs

AU - Cozzarini, Cesare

AU - Rancati, Tiziana

AU - Badenchini, Fabio

AU - Palorini, Federica

AU - Avuzzi, Barbara

AU - Degli Esposti, Claudio

AU - Girelli, Giuseppe

AU - Improta, Ilaria

AU - Vavassori, Vittorio

AU - Valdagni, Riccardo

AU - Fiorino, Claudio

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Aim: To assess the predictors of the onset of impotence 1 year after radiotherapy for prostate cancer. Patients and methods: In a multi-centric prospective study, the International Index of Erectile Function (IIEF) questionnaire-based potency of 91 hormone-naïve and potent patients (IIEF1-5 > 11 before radiotherapy) was assessed. At the time of this analysis, information on potency 1 year after treatment was available for 62 of 91 patients (42 treated with hypofractionation: 2.35–2.65 Gy/fr, 70–74.2 Gy; 20 with conventional fractionation: 74–78 Gy). Prospectively collected individual information and Dmax/Dmeanto the penile bulb were available; the corresponding 2 Gy-equivalent values (EQD2_max/EQD2_mean) were also considered. Predictors of 1‑year impotency were assessed through uni- and multi-variable backward logistic regression: The best cut-off values discriminating between potent and impotent patients were assessed by ROC analyses. The discriminative power of the models and goodness-of-fit were measured by AUC analysis and the Hosmer–Lemeshow (H&L) test. Results: At 1‑year follow-up, 26 of 62 patients (42 %) became impotent. The only predictive variables were baseline IIEF1-5 values (best cut-off baseline IIEF1-5 ≥ 19), Dmax≥ 68.5 Gy and EQD2_max≥ 74.2 Gy. The risk of 1‑year impotence may be predicted by a two-variable model including baseline IIEF1-5 (OR: 0.80, p = 0.003) and EQD2_max≥ 74.2 Gy (OR: 4.1, p = 0.022). The AUC of the model was 0.77 (95% CI: 0.64–0.87, p = 0.0007, H&L: p = 0.62). The 1‑year risk of impotency after high-dose radiotherapy in potent men depends on the EQD2_maxto the penile bulb and on baseline IIEF1-5 values. Conclusion: A significant reduction in the risk may be expected mainly when sparing the bulb in patients with no/mild baseline impotency (IIEF1-5 > 17).

AB - Aim: To assess the predictors of the onset of impotence 1 year after radiotherapy for prostate cancer. Patients and methods: In a multi-centric prospective study, the International Index of Erectile Function (IIEF) questionnaire-based potency of 91 hormone-naïve and potent patients (IIEF1-5 > 11 before radiotherapy) was assessed. At the time of this analysis, information on potency 1 year after treatment was available for 62 of 91 patients (42 treated with hypofractionation: 2.35–2.65 Gy/fr, 70–74.2 Gy; 20 with conventional fractionation: 74–78 Gy). Prospectively collected individual information and Dmax/Dmeanto the penile bulb were available; the corresponding 2 Gy-equivalent values (EQD2_max/EQD2_mean) were also considered. Predictors of 1‑year impotency were assessed through uni- and multi-variable backward logistic regression: The best cut-off values discriminating between potent and impotent patients were assessed by ROC analyses. The discriminative power of the models and goodness-of-fit were measured by AUC analysis and the Hosmer–Lemeshow (H&L) test. Results: At 1‑year follow-up, 26 of 62 patients (42 %) became impotent. The only predictive variables were baseline IIEF1-5 values (best cut-off baseline IIEF1-5 ≥ 19), Dmax≥ 68.5 Gy and EQD2_max≥ 74.2 Gy. The risk of 1‑year impotence may be predicted by a two-variable model including baseline IIEF1-5 (OR: 0.80, p = 0.003) and EQD2_max≥ 74.2 Gy (OR: 4.1, p = 0.022). The AUC of the model was 0.77 (95% CI: 0.64–0.87, p = 0.0007, H&L: p = 0.62). The 1‑year risk of impotency after high-dose radiotherapy in potent men depends on the EQD2_maxto the penile bulb and on baseline IIEF1-5 values. Conclusion: A significant reduction in the risk may be expected mainly when sparing the bulb in patients with no/mild baseline impotency (IIEF1-5 > 17).

KW - Dose-response

KW - Erectile dysfunction

KW - Predictive models

KW - Prostate cancer

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=84963783811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963783811&partnerID=8YFLogxK

U2 - 10.1007/s00066-016-0964-1

DO - 10.1007/s00066-016-0964-1

M3 - Articolo

AN - SCOPUS:84963783811

VL - 192

SP - 297

EP - 304

JO - Strahlentherapie und Onkologie

JF - Strahlentherapie und Onkologie

SN - 0179-7158

IS - 5

ER -